Australia’s Cervical Cancer Success Story: Can It Be Sustained?
Australia is on the cusp of eliminating cervical cancer as a public health problem, a feat largely attributed to decades of proactive prevention strategies. However, a recent report from the NHMRC Centre of Research Excellence in Cervical Cancer Control (C4) reveals concerning declines in vaccination and screening rates, potentially jeopardizing this hard-won progress.
A History of Prevention: From Pap Tests to HPV Vaccines
The journey began in 1991 with the introduction of the National Cervical Cancer Screening Program, utilizing Pap tests to detect precancerous cell changes. This initiative halved cervical cancer incidence and mortality. In 2007, Australia pioneered the world’s first national HPV vaccination program, dramatically reducing HPV infection rates and the incidence of cervical pre-cancers.
Further bolstering these efforts, the screening program transitioned to HPV testing in 2017, focusing on HPV types 16 and 18 – responsible for the majority of cervical cancers. This shift is projected to reduce cervical cancer rates by an additional 20-30%. The introduction of a nine-valent HPV vaccine in 2018, protecting against nine cancer-causing HPV types, further strengthened the preventative arsenal.
Elimination Strategy and Encouraging Results
In 2023, Australia launched a national cervical cancer elimination strategy, setting ambitious five-year goals: 90% HPV vaccination coverage for both girls and boys, 70% screening participation for women aged 25-75 and 95% treatment of detected pre-cancers and cancers.
The latest data offers encouraging signs. Cervical cancer rates are slowly declining – from 6.6 cases per 100,000 women in 2020 to 6.3 in 2021. Remarkably, no cases of cervical cancer were diagnosed in women under 25 in 2021, a direct result of the HPV vaccination program. HPV infection rates, particularly among younger women, are also decreasing, with only 1% of women aged 25-29 testing positive for HPV types 16 or 18. Approximately 85% of women aged 35-39 have undergone HPV testing at least once, significantly reducing their individual risk.
The Threat of Declining Uptake
Despite these successes, vaccination and screening rates have been falling since the onset of the pandemic. HPV vaccination coverage decreased from 85.7% in 2020 to 79.5% in 2024. Screening participation is also down, with over one in four women currently overdue for their cervical cancer screening.
Experts emphasize the safety and effectiveness of the HPV vaccine. Professor Julia Brotherton of the University of Melbourne urges parents to view vaccination as a “gift” protecting their child’s long-term health, and encourages those who missed school vaccinations to consult their healthcare provider for a catch-up dose.
Associate Professor Megan Smith from the University of Sydney’s Cancer Elimination Collaboration highlights the need for tailored screening strategies, particularly HPV self-collection, to improve participation rates.
Addressing Health Inequalities
The report underscores the importance of equitable access to prevention services. Indigenous Australians experience nearly double the national cervical cancer rate, with a significantly higher mortality rate. Addressing this disparity requires improved data collection and the development of targeted solutions.
Epidemiologist Dorothy Machalek of the Kirby Institute stresses the need to focus efforts on ensuring that all groups benefit from the national elimination strategy, particularly those at high risk of being left behind.
Looking Ahead: Recommendations for Continued Progress
The C4 report recommends revitalizing school vaccination programs, improving access for Aboriginal and Torres Strait Islander adolescents, piloting innovative screening methods, and enhancing national health data systems. Continued investment and consistent messaging are crucial to maintaining momentum and achieving complete cervical cancer elimination.
Frequently Asked Questions
- What is HPV? HPV (human papillomavirus) is a common virus that can cause cervical cancer.
- How effective is the HPV vaccine? The HPV vaccine is highly effective in preventing HPV infection and reducing the risk of cervical cancer.
- How often should I get screened for cervical cancer? Women aged 25-75 should be screened every five years.
- What is HPV self-collection? It’s a method where individuals can collect their own sample for HPV testing, increasing accessibility and participation.
Learn more: Explore the full 2025 Cervical Cancer Elimination Progress Report from the NHMRC Centre of Research Excellence in Cervical Cancer Control.
Keep reading